- Proven diagnosis of locally advanced or metastatic non-squamous cell carcinoma of the
- Positive for translocation or inversion events involving the ALK gene locus
- Patients must have had progressive disease after only one prior chemotherapy regimen.
This regimen must have been platinum-based and may have included maintenance therapy.
- Evidence of personally signed and dated informed consent document indicating that the
patient (or legally acceptable representative) has been informed of all the pertinent
aspects of the trial prior to enrollment.
- Current treatment on another therapeutic clinical trial.
- Prior therapy directly targeting ALK.
- Any of the following within the 3 months prior to starting study treatment:
myocardial infarction, severe/unstable angina, coronary/peripheral artery bypass
graft, congestive heart failure, or cerebrovascular accident including transient
- Ongoing cardiac dysrhythmias of NCI CTCAE Grade >=2, uncontrolled atrial fibrillation
of any grade, or QTc interval >470 msec.
- Pregnancy or breastfeeding.
- Use of drugs or foods that are known potent CYP3A inducers/inhibitors/substrates with
narrow therapeutic indices.
- Known HIV infection
- Known interstitial lung disease or interstitial fibrosis
- Other severe acute or chronic medical conditions (including severe gastrointestinal
conditions such as diarrhea or ulcer) or psychiatric conditions, or laboratory
abnormalities that would impart, in the judgment of the investigator and/or sponsor,
excess risk associated with study participation or study drug administration, and
which would, therefore, make the patient inappropriate for entry into this study.